CN106397527A - 米非司酮衍生物及其用途 - Google Patents

米非司酮衍生物及其用途 Download PDF

Info

Publication number
CN106397527A
CN106397527A CN201610821694.4A CN201610821694A CN106397527A CN 106397527 A CN106397527 A CN 106397527A CN 201610821694 A CN201610821694 A CN 201610821694A CN 106397527 A CN106397527 A CN 106397527A
Authority
CN
China
Prior art keywords
phenyl
nmr
cdcl
methyl
mifepristone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201610821694.4A
Other languages
English (en)
Other versions
CN106397527B (zh
Inventor
陈策实
陈海军
刘蓉
林雨琦
郑政
赵平
杨传雨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kunming Institute of Zoology of CAS
Fuzhou University
Original Assignee
Kunming Institute of Zoology of CAS
Fuzhou University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kunming Institute of Zoology of CAS, Fuzhou University filed Critical Kunming Institute of Zoology of CAS
Priority to CN201610821694.4A priority Critical patent/CN106397527B/zh
Publication of CN106397527A publication Critical patent/CN106397527A/zh
Application granted granted Critical
Publication of CN106397527B publication Critical patent/CN106397527B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

本发明公开了一种米非司酮衍生物及其用途。所述的米非司酮衍生物的结构式如式(I)所示；其中R为酰基或者磺酰基；本发明还涉及米非司酮衍生物在制备治疗与KLF5调控的肿瘤药物中的用途，特别是治疗三阴性乳腺癌药物中的用途。该化合物结构简单，易于制备；抗肿瘤活性较米非司酮强，且剂量小，可用于治疗三阴性乳腺癌及与KLF5密切相关的肿瘤药物的制备，同时，本发明探索合成的一类具有高成药性的米非司酮衍生物，也为其他同类化合物的合成提供新的解决思路和方案。

Description

米非司酮衍生物及其用途
技术领域
本发明属于医药技术领域，具体涉及米非司酮衍生物及其用途。
背景技术
研究发现，转录因子KLF5(Kruppel-like factor 5,锌指蛋白转录因子5)是与DNA结构域结合的转录调控因子家族。在正常组织中KLF5参与众多细胞的生物学进程，包括细胞的增殖、分化、迁移、炎症以及潜能性。在癌症组织中KLF5的表达和功能均有所改变，并参与调节癌细胞的增殖、调控、转移、肿瘤微环境以及肿瘤干细胞。KLF5主要参与许多控制细胞增殖的重要信号通路，无论在正常细胞还是在人类许多癌细胞中都具有促使细胞增殖的作用。三阴性乳腺癌(Triple Negative Breast Cancer,TNBC)，是雌激素受体(ER)、孕激素受体(PR)和人表皮生长因子受体(HER2)均为阴性的一种特殊类型的乳腺癌，是乳腺癌中恶性程度最高的一种亚型，约占所有乳腺癌的10％-25％，至今仍未找到有效的靶向治疗药物。在乳腺癌细胞中，KLF5通过上调基因Cyclin A和DNA复制因子1(CDT1)等促进乳腺癌细胞增殖。也有研究发现KLF5主要通过上调靶基因FGF-BP(Fibroblast growth factorbinding protein1)起促进细胞增殖的作用，同时促进ERK激酶活性，稳定MKP-1蛋白表达促进细胞生存。此外，KLF5在乳腺癌的发生发展过程中，起到很重要的作用。乳腺癌的KLF5在ER阴性乳腺癌中普遍高表达，且KLF5高表达的患者生存时间显著短于KLF5低表达的病人。前期研究也发现KLF5转录因子在Luminal类型的乳腺癌细胞T47D细胞中能够被孕激素所诱导，而该过程能够由孕激素受体抑制剂米非司酮(Mifepristone，MIF)所阻断。
前期新药筛选结果发现，米非司酮(Mifepristone)能够抑制三阴性乳腺癌细胞增殖、诱导细胞凋亡，并且在较高剂量下能够抑制人源性三阴性乳腺癌移植瘤在免疫缺陷小鼠体内的生长。进一步作用机制研究还发现米非司酮是通过诱导三阴性乳腺癌细胞中微小RNA-153的表达，从而抑制乳腺癌的增殖、生存和细胞干性的转录因子KLF5的表达(Theranostics 2016,6,533-44)。但是大量研究数据和前期活性测试结果均显示米非司酮必须在较高剂量下才能产生抗肿瘤活性，而且米非司酮的主要代谢产物单去甲基米非司酮(RU-42633,美她司酮)则没有明显的抗肿瘤活性。鉴于米非司酮在体内很快就代谢为单去甲基米非司酮，而且这个主要代谢产物在给药后0.5-2小时后血液中的浓度远超过母体化合物，大大限制了米非司酮可能作为一种较为理想的靶向抗肿瘤药物的进一步临床应用。
发明内容
针对以上技术问题，因此，本发明提供一类米非司酮衍生物，以其作为高效抗癌药物的活性成份，从而为寻找抗三阴性乳腺癌的靶向药物开辟新的途径。
基、苯基取代苯基、烯烃、苯基取代烯烃或杂环，包括噻唑、2-噻吩、吡嗪、吡啶、卤代吡啶；当R为磺酰基时，其具体结构特征为R2SO2-，R2为苯基、C1-C6烷基取代苯基。
优选地，当R为酰基时，其中R1为氯代C1-C6烷基、卤代苯基、萘基、硝基取代苯基、C1-C6烷基取代苯基或苯基取代苯基。进一步优选地，R1为氯代甲烷基。优选地，R1为氯或溴代苯基。更加优选地，R1为3，4氯代苯基或2-溴4-氯代苯基。
优选地，R1为苯基或甲基取代苯基。更加优选地，R1为甲基取代3-苯基或甲基取代4-苯基。
本发明的米非司酮衍生物通过如下方法制备：
方法a：将1.0当量美她司酮和1.5当量的酰基氯或磺酰氯加入到0.1-0.2M乙酸乙酯溶液中，在0℃时加入3.0当量的三乙胺，将所得混合物在室温下搅拌16小时，然后用乙酸乙酯稀释该溶液，并用1M盐酸溶液和盐水洗涤。用无水硫酸钠干燥有机层，然后在减压下浓缩，残余物经石油醚/乙酸乙酯比例为4/1:1/1硅胶柱色谱法的柱层析，得到所需产物。
方法b：将1.2-2.0当量的一元芳香羧酸，1.0当量的美她司酮，1.5-2.0当量的苯并三氮唑-N,N,N',N'-四甲基脲六氟磷酸盐和0.1-0.2M的N,N-二甲基甲酰胺，2.0-4.0当量的N，N-二异丙基乙胺混合，然后将该混合物在室温下搅拌直到美她司酮被反应完全，并通过薄层色谱法测定；用乙酸乙酯稀释混合物并用1M盐酸水溶液淬灭；用水和盐水洗涤洗涤有机层后，用无水硫酸钠干燥，并减压浓缩，将粗物质通过硅胶柱色谱法柱层析或用薄层色谱法纯化后，得到所需产物。
方法c：将1.2-2.0当量的一元芳香羧酸，1.0当量的美她司酮和3.0当量的1-乙基-(3-二甲基氨基丙基)碳酰二亚胺盐酸盐，0.1-0.2M二氯甲烷混合，让混合物在室温下搅拌直到美她司酮被反应完全，通过薄层色谱法测定；用二氯甲烷稀释混合物并用1M盐酸水溶液淬灭；用水和盐水洗涤有机层，并用无水硫酸钠干燥，然后减压浓缩，将粗物质通过硅胶柱色谱法柱层析或用薄层色谱法纯化后，得到所需产物。
其中，所述的美她司酮Metapristone的制备方法参照前期研究结果及专利CN201310510394.0，名称为“一种合成美她司酮的方法”。
通常用TLC来跟踪测定反应的完成程度，反应完毕后一般用冰水淬灭，用乙酸乙酯、二氯甲烷、三氯甲烷等萃取，依次用水、饱和食盐水洗涤，干燥，低温减压除去溶剂，经柱层析得到最终产物，得到产物用核磁共振、高分辨质谱等方法验证其结构。
本发明的另一目的在于提供本发明米非司酮衍生物的用途，特别是在制备治疗与KLF5调控相关肿瘤方面的药物中的用途。
进一步地，本发明米非司酮衍生物在制备治疗三阴性乳腺癌药物中的用途。
本发明的有益效果：
1)本发明在前期探索工作的基础上，通过骨架再利用的药物设计原理，以米非司酮代谢敏感结构区域为结构改造位点，合理设计聚焦型化合物库，通过系统的结构优化，设计与合成了一类米非司酮衍生物，提供了米非司酮衍生物的结构式，该化合物结构简单易于制备且稳定，该米非司酮衍生物较米非司酮抗肿瘤活性强。
2)本发明的米非司酮衍生物作为治疗三阴性乳腺癌的药物活性较米非司酮强，且剂量小。
3)本发明提供的米非司酮衍生物用于制备成治疗三阴性乳腺癌的药物，为其他同类化合物的合成提供新的解决思路和方案。
具体实施方式
下述制备实施例中，用NMR定标：δH/C 7.26/77.16ppm(CDCl3)；试剂主要由安耐吉试剂公司提供，产品纯化主要用柱色谱法，硅胶(200-300目或300-400目)，柱色谱法所用硅胶由阿达玛斯试剂公司提供(cas：63231-67-4)。
下述缩写词：EtOAc:乙酸乙酯；Et3N：三乙胺；Na2SO4：硫酸钠；PE：石油醚；HBTU：苯并三氮唑-N,N,N',N'-四甲基脲六氟磷酸盐；DMF：N,N-二甲基甲酰胺；DIPEA：N，N-二异丙基乙胺；TLC：硅胶色谱板；EDCI：1-乙基-(3-二甲基氨基丙基)碳酰二亚胺盐酸盐；CH2Cl2：二氯甲烷。
实施例1 FZU-0000-005
2-Chloro-N-(4-((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-(prop-1-yn-1-yl)-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-11-yl)phenyl)-N-methylacetamide
将28mg,0.24mmol 2-氯乙酰氯,84mg,0.2mmol美她司酮和42mg,0.4mmol Et3N加入到2.0mL EtOAc中搅拌16小时，PE/EtOAc＝1:1，按方法(a)制备得到90mg产物，得率92％，产物为白色固体，mp:124.3–125.5℃。
所得的产物进行氢谱1HNMR、碳谱13CNMR及HRMS检测，结果如下：1H NMR(400MHz,CDCl3)δ7.27(d,J＝6.0Hz,2H),7.16(d,J＝7.7Hz,2H),5.80(s,1H),4.47(d,J＝6.9Hz,1H),3.82(s,2H),3.27(s,3H),2.85–2.75(m,1H),2.67–2.56(m,2H),2.53–2.38(m,4H),2.37–2.15(m,4H),2.10–2.01(m,1H),2.01–1.94(m,1H),1.91(s,3H),1.79–1.72(m,2H),1.56–1.47(m,1H),1.41–1.32(m,1H),0.50(s,3H).
13C NMR(101MHz,CDCl3)δ199.40,166.42,156.52,145.54,144.96,140.31,129.93,128.68,127.12,123.32,82.75,82.21,80.03,49.75,46.96,41.54,40.19,39.27,39.16,38.96,38.08,36.81,31.13,27.36,25.99,23.40,13.97,3.94.
HRMS(ESI-TOF):calcd for C30H35ClNO3[M+H]+492.2300；found 492.2290.
实施例2
2-Chloro-N-(4-((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-(prop-1-yn-1-yl)-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-11-yl)phenyl)-N-methylpropan amide(FZU-0010-001)
与实施例1不同之处在于：2-氯乙酰氯为30mg,Et3N为40mg，得到80mg产物，得率为79％，其中PE/EtOAc＝2:1.产物为白色固体，mp:124.6–125.6℃。
1H NMR(400MHz,CDCl3)δ7.27(d,J＝7.9Hz,2H),7.18(d,J＝8.0Hz,2H),5.80(s,1H),4.48(d,J＝6.8Hz,1H),4.26(q,J＝6.3Hz,1H),3.28(s,3H),2.90–2.74(m,1H),2.68–2.58(m,2H),2.54–2.38(m,4H),2.32–2.19(m,2H),2.13–1.95(m,4H),1.91(s,3H),1.83–1.67(m,2H),1.56(d,J＝6.5Hz,3H),1.53–1.44(m,1H),1.40–1.28(m,1H),0.51(s,3H).13CNMR(101MHz,CDCl3)δ199.43,169.57,156.55,145.37,145.09,140.51,129.98,128.61,127.30,123.37,82.82,82.26,80.11,49.85,47.01,40.25,39.29,39.19,39.02,38.15,36.85,31.16,27.41,26.04,23.44,21.36,14.00,13.99,3.94.
HRMS(ESI-TOF):calcd for C31H37ClNO3[M+H]+506.2456；found 506.2456.
实施例3
N-(4-((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-(prop-1-yn-1-yl)-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-11-yl)phenyl)-N,4-dimethylbenzenesulfo namide(FZU-0025-008)
与实施例1不同之处在于：用46mg，0.24mmol的对甲基苯磺酰氯替换28mg,0.24mmol 2-氯乙酰氯，根据方法a得到83mg白色固体，收率73％，mp:121.8–122.9℃。
1H NMR(400MHz,CDCl3)δ7.33(d,J＝7.9Hz,2H),7.19(d,J＝7.9Hz,2H),7.11(d,J＝8.2Hz,2H),7.01(d,J＝8.2Hz,2H),5.78(s,1H),4.42(d,J＝6.8Hz,1H),3.11(s,3H),2.87–2.66(m,1H),2.66–2.56(m,2H),2.51–2.36(m,6H),2.34–2.18(m,4H),2.14–1.97(m,3H),1.91(s,3H),1.82–1.68(m,2H),1.55–1.44(m,1H),1.35–1.28(m,1H),0.51(s,3H).
13C NMR(101MHz,CDCl3)δ199.42,156.61,145.44,143.74,143.60,139.14,133.03,129.62,129.24,127.81,127.34,126.24,123.07,82.65,82.20,80.02,49.71,46.93,40.07,39.17,39.12,38.87,37.78,36.78,31.08,27.31,25.84,23.34,21.57,13.74,3.86.
HRMS(ESI-TOF):calcd for C35H40NO4S[M+H]+592.2492；found 592.2472.
实施例4
N-(4-((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-(prop-1-yn-1-yl)-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-11-yl)phenyl)-N-methylbenzenesulfonamide(FZU-0025-009)
与实施例1不同之处在于：用113mg，0.64mmol的苯磺酰氯替换28mg,0.24mmol 2-氯乙酰氯，将作为起始原料，根据方法a.得到63mg白色固体，收率57％，mp:120.3–121.5℃℃。
1H NMR(400MHz,CDCl3)δ7.58–7.54(m,1H),7.46(d,J＝7.2Hz,2H),7.40(d,J＝7.9Hz,2H),7.15–7.07(m,2H),7.02–6.96(m,2H),5.79(s,1H),4.42(d,J＝6.8Hz,1H),3.15(s,3H),2.85–2.73(m,1H),2.65–2.57(m,2H),2.54–2.35(m,5H),2.32–2.20(m,3H),2.11–1.98(m,3H),1.88(s,3H),1.80–1.67(m,2H),1.57–1.43(m,1H),1.40–1.31(m,1H),0.51(s,3H).
13C NMR(101MHz,CDCl3)δ199.40,156.58,145.35,143.87,138.98,135.93,132.82,129.65,128.99,128.92,128.62,127.74,127.39,127.32,126.25,124.95,123.10,82.68,82.19,80.02,49.71,46.93,40.05,39.18,39.10,38.88,37.86,36.78,31.07,27.31,25.84,23.34,13.77,3.86.
HRMS(ESI-TOF):calcd for C34H38NO4S[M+H]+578.2336；found 578.2314.
实施例5
3,4-Dichloro-N-(4-((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-(prop-1-yn-1-yl)-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-11-yl)phenyl)-N-methylbenzamide(FZU-0000-008)
取8mg,0.24mmol 3,4-二氯苯甲酸、84mg,0.2mmol的美她司酮、112mg,0.6mmol的HBTU和76mg,0.6mmol DIPEA加入2.0mL DMF中搅拌16小时，PE/EtOAc＝2:1，按方法b制备得到84mg产物，得率为71％，产物为白色固体，mp:230.1–231.5℃。
1H NMR(400MHz,CDCl3)δ7.32(s,1H),7.12(d,J＝8.3Hz,1H),7.04(d,J＝8.0Hz,2H),7.01(d,J＝8.6Hz,1H),6.89(d,J＝7.9Hz,2H),5.72(s,1H),4.33(d,J＝6.9Hz,1H),3.42(s,3H),2.75–2.62(m,1H),2.60–2.48(m,2H),2.46–2.24(m,5H),2.23–2.09(m,3H),2.02–1.88(m,2H),1.83(s,3H),1.76–1.60(m,2H),1.49–1.36(m,1H),1.35–1.24(m,1H),0.38(s,3H).
13C NMR(101MHz,CDCl3)δ199.30,167.82,156.47,145.04,144.11,141.82,135.51,133.91,131.97,130.98,129.70,129.59,128.17,128.10,126.91,123.15,82.47,82.25,79.92,49.57,46.87,40.01,39.21,39.06,38.85,38.33,36.70,31.08,27.32,25.77,23.31,13.73,3.87.
HRMS(ESI-TOF):calcd for C35H36Cl2NO3[M+H]+588.2067；found 588.2058.
实施例6
3-Chloro-N-(4-((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-(prop-1-yn-1-yl)-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-11-yl)phenyl)-N-methylbenza mide(FZU-0002-016)
与实施例5不同之处在于：将8mg,0.24mmol 3,4-二氯苯甲酸替换为47mg,0.3mmol3-氯苯甲酸，HBTU为152mg,0.4mmol，DIPEA为103mg,0.8mmol，得100mg产物，得率为90％。产物为白色固体，mp:122.6–123.7℃。
1H NMR(400MHz,CDCl3)δ7.27(s,1H),7.19(d,J＝7.7Hz,1H),7.15–6.99(m,4H),6.94(d,J＝7.7Hz,2H),5.77(s,1H),4.36(d,J＝7.2Hz,1H),3.45(s,3H),2.80–2.67(m,1H),2.65–2.53(m,2H),2.51–2.30(m,4H),2.28–2.13(m,3H),2.05–1.97(m,1H),1.96–1.91(m,1H),1.89(s,3H),1.84–1.80(m,1H),1.80–1.66(m,2H),1.54–1.42(m,1H),1.38–1.27(m,1H),0.36(s,3H).
13C NMR(101MHz,CDCl3)δ199.43,168.98,156.54,145.17,143.90,142.12,137.54,133.74,129.80,129.05,128.95,128.02,127.06,127.02,123.23,82.72,82.25,80.09,49.65,46.91,40.10,39.30,39.19,38.92,38.70,38.29,36.81,31.17,27.41,25.83,23.39,13.78,3.93.
HRMS(ESI-TOF):calcd for C35H35ClNO3[M-H]-552.2311；found 552.2293.
实施例7
3,6-Dichloro-N-(4-((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-(prop-1-yn-1-yl)-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-11-yl)phenyl)-N-methylpicolinamide(FZU-0010-006)
与实施例5不同之处在于：将8mg,0.24mmol 3,4-二氯苯甲酸替换为46mg,0.24mmol 3,6-二氯吡啶甲酸，HBTU为114mg,0.3mmol，DIPEA为52mg,0.4mmol，PE/EtOAc＝1:1，得164mg产物，得率为99％。产物为白色固体，mp:126.5–127.6℃。
1H NMR(400MHz,CDCl3)δ7.41(d,J＝8.4Hz,1H),7.15–7.03(m,3H),7.03–6.96(m,2H),5.75(s,1H),4.30(d,J＝7.2Hz,1H),3.46(s,3H),2.72–2.60(m,1H),2.60–2.51(m,2H),2.48–2.26(m,4H),2.24–2.07(m,3H),2.05–1.95(m,2H),1.95–1.90(m,1H),1.87(s,3H),1.77–1.63(m,2H),1.49–1.37(m,1H),1.35–1.25(m,1H),0.21(s,3H).
13C NMR(101MHz,CDCl3)δ199.40,164.94,156.52,153.28,148.52,145.11,144.81,139.73,139.53,129.79,127.68,127.38,127.10,124.98,123.23,82.77,82.18,80.05,49.61,46.78,40.12,39.39,39.17,38.86,36.80,36.68,31.13,27.39,25.81,23.39,13.32,3.90.
HRMS(ESI-TOF):calcd for C34H35Cl2N2O3[M+H]+589.2019；found 589.2020.
实施例8
5-Chloro-N-(4-((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-(prop-1-yn-1-yl)-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-11-yl)phenyl)-N-methylnicotinamide(FZU-0010-008)
与实施例7不同之处在于：将46mg,0.24mmol的3,6-二氯吡啶甲酸替换为38mg,0.24mmol的5-氯烟酸，得到109mg产物，得率为98％，产物为白色固体，mp:118.9–120.1℃℃。
1H NMR(400MHz,CDCl3)δ8.37(s,1H),8.32(s,1H),7.50(s,1H),7.08(d,J＝8.0Hz,2H),6.94(d,J＝7.9Hz,2H),5.75(s,1H),4.34(d,J＝7.1Hz,1H),3.46(s,3H),2.76–2.64(m,1H),2.60–2.50(m,2H),2.49–2.31(m,4H),2.29–2.26(m,1H),2.24–2.10(m,4H),2.08–1.93(m,3H),1.93–1.88(m,1H),1.86(s,3H),1.67(dt,J＝11.4,9.4Hz,2H),1.48–1.38(m,1H),1.35–1.27(m,1H),0.38(s,3H).
13C NMR(101MHz,CDCl3)δ199.39,166.53,156.47,149.24,147.41,144.93,144.66,141.38,135.87,132.77,131.26,129.87,128.39,127.23,123.30,82.64,82.26,80.04,49.66,46.90,40.10,39.26,39.15,38.95,38.32,36.79,31.15,27.38,25.86,23.38,13.86,3.92.
HRMS(ESI-TOF):calcd for C34H36ClN2O3[M+H]+555.2409；found 555.2397.
实施例9
5-Chloro-N-(4-((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-(prop-1-yn-1-yl)-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-11-yl)phenyl)-N-methylpicolinamide(FZU-0010-009)
与实施例8不同之处在于：5-氯烟酸为45mg,0.28mmol，HBTU为152mg,0.4mmol，得到120mg产物，得率为90％。产物为白色固体，mp:124.1–125.5℃。
1H NMR(400MHz,CDCl3)δ8.17(s,1H),7.54(d,J＝6.6Hz,1H),7.48–7.35(m,1H),7.14–6.84(m,4H),5.77(s,1H),4.36(d,J＝6.8Hz,1H),3.48(s,3H),2.79–2.66(m,1H),2.62–2.53(m,2H),2.51–2.29(m,4H),2.28–2.16(m,3H),2.14–2.07(m,1H),2.06–1.90(m,3H),1.88(s,3H),1.80–1.66(m,1H),1.53–1.41(m,1H),1.38–1.28(m,1H),0.35(s,3H).
13C NMR(101MHz,CDCl3)δ199.40,167.71,156.55,152.17,147.14,145.25,143.64,141.87,135.98,132.38,129.72,127.74,126.90,124.76,123.20,82.69,82.26,80.04,49.70,46.95,40.07,39.30,39.13,38.93,37.90,36.81,31.13,27.37,25.86,23.39,13.63,3.92.
实施例10
4-Chloro-N-(4-((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-(prop-1-yn-1-yl)-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-11-yl)phenyl)-N-methylpicolinamide(FZU-0010-010)
与实施例9不同之处在于：将5-氯烟酸替换为4-氯烟酸，得到140mg产物，产率为90％，PE/EtOAc＝1:2。产物为白色固体，mp:121.3–122.5℃。
1H NMR(400MHz,CDCl3)δ8.12(d,J＝8.0Hz,1H),7.46(s,1H),7.12(d,J＝8.0Hz,1H),7.03(d,J＝8.0Hz,2H),6.95(d,J＝8.0Hz,2H),5.77(s,1H),4.36(d,J＝6.3Hz,1H),3.50(s,3H),2.80–2.65(m,1H),2.65–2.52(m,2H),2.51–2.30(m,4H),2.28–2.10(m,4H),2.06–1.93(m,2H),1.88(s,3H),1.80–1.57(m,2H),1.53–1.42(m,1H),1.35–1.23(m,1H),0.36(s,3H).
13C NMR(101MHz,CDCl3)δ199.44,167.41,156.59,155.52,149.18,145.29,144.40,143.74,141.75,129.72,127.79,126.86,124.36,124.28,123.19,82.72,82.25,80.05,49.67,46.90,40.09,39.27,39.17,38.89,37.93,36.82,31.14,27.38,25.83,23.38,13.63,3.91.
HRMS(ESI-TOF):calcd for C34H36ClN2O3[M+H]+555.2409；found 588.2401.
实施例11
6-Chloro-N-(4-((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-(prop-1-yn-1-yl)-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-11-yl)phenyl)-N-methylnicotinamide(FZU-0010-012)
与实施例9不同之处在于：将5-氯烟酸替换为6-氯烟酸，得到116mg产物，产率为90％，
PE/EtOAc＝2：3。产物为白色固体，mp:127.2–128.4℃。
1H NMR(400MHz,CDCl3)δ8.27(s,1H),7.41(d,J＝8.0Hz,1H),7.07(d,J＝8.1Hz,2H),7.03(d,J＝8.3Hz,1H),6.93(d,J＝8.0Hz,2H),5.75(s,1H),4.35(d,J＝7.0Hz,1H),3.45(s,3H),2.71(dt,J＝14.8,5.0Hz,1H),2.60–2.48(m,2H),2.48–2.28(m,4H),2.27–2.12(m,4H),2.05–1.92(m,3H),1.86(s,3H),1.76–1.62(m,2H),1.51–1.38(m,1H),1.35–1.24(m,1H),0.36(s,3H).
13C NMR(101MHz,CDCl3)δ199.40,167.01,156.48,152.17,150.02,144.90,144.55,141.54,138.75,130.63,129.88,128.35,127.28,123.30,123.20,82.69,82.20,80.03,49.69,46.97,40.04,39.29,39.06,38.96,38.28,36.77,31.11,27.34,25.88,23.36,13.85,3.93.
HRMS(ESI-TOF):calcd for C34H36ClN2O3[M+H]+555.2409；found 555.2401.
实施例12
2-Chloro-N-(4-((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-(prop-1-yn-1-yl)-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-11-yl)phenyl)-N-methylisonicotinamide(FZU-0010-014)
与实施例9不同之处在于：将5-氯烟酸替换为2-氯烟酸，得到100mg产物，产率为90％，PE/EtOAc＝2：3。产物为白色固体，mp:117.5–118.6℃。
1H NMR(400MHz,CDCl3)δ8.30(s,1H),7.44(d,J＝7.9Hz,1H),7.11(d,J＝6.9Hz,2H),7.06(d,J＝7.4Hz,1H),6.96(d,J＝6.8Hz,2H),5.78(s,1H),4.38(d,J＝5.4Hz,1H),3.49(s,3H),2.81–2.68(m,1H),2.64–2.54(m,2H),2.52–2.30(m,4H),2.29–2.17(m,4H),2.09–1.94(m,3H),1.90(s,3H),1.79–1.65(m,2H),1.53–1.41(m,1H),1.40–1.29(m,1H),0.36(s,3H).
13C NMR(101MHz,CDCl3)δ199.38,167.01,156.46,152.17,150.04,144.89,144.54,141.55,138.74,130.63,129.88,128.35,127.29,123.31,123.19,82.70,82.20,80.03,49.70,46.97,40.04,39.28,39.06,38.96,38.28,36.78,31.11,27.34,25.88,23.36,13.84,3.93.
HRMS(ESI-TOF):calcd for C34H36ClN2O3[M+H]+555.2409；found 555.2401.
实施例13
Following the General Procedure C:
N-(4-((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-(prop-1-yn-1-yl)-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-11-yl)phenyl)-N-methylpicolinamide(FZU-0002-018)
将37mg,0.3mmol的吡啶甲酸，84mg,0.2mmol的美她司酮，115mg,0.6mmol的EDCI加入到2.0mL CH2Cl2中，按方法C制备得到102mg的产物，得率为98％，PE/EtOAc＝1:3，产物为黄色固体，mp:116.3–117.4℃。
1H NMR(400MHz,CDCl3)δ8.36–8.15(m,1H),7.60–7.44(m,1H),7.41–7.28(m,1H),7.17–6.74(m,5H),5.73(s,1H),4.31(d,J＝6.6Hz,1H),3.47(s,3H),2.74–2.62(m,1H),2.60–2.49(m,2H),2.46–2.25(m,4H),2.23–2.08(m,5H),2.06–1.91(m,2H),1.85(s,3H),1.76–1.59(m,2H),1.51–1.35(m,1H),1.33–1.21(m,1H),0.34(s,3H).
13C NMR(101MHz,CDCl3)δ199.49,168.79,156.64,154.21,148.37,145.42,143.41,141.99,136.19,129.65,127.65,126.87,123.93,123.75,123.12,82.69,82.25,80.03,49.65,46.89,40.07,39.27,39.16,38.87,37.79,36.81,31.12,27.35,25.80,23.38,13.66,3.90.
HRMS(ESI-TOF):calcd for C34H35N2O3[M-H]-519.2653；found 519.2623.
实施例14
N-(4-((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-(prop-1-yn-1-yl)-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-11-yl)phenyl)-N-methylbenzamide(FZU-0002-006)
将44mg,0.36mmol的吡啶甲酸，125mg,0.3mmol的美她司酮，173mg,0.9mmol的EDCI加入到3.0mL CH2Cl2中，按方法C制备得到120mg的产物，得率为77％，PE/EtOAc＝1:1，产物为白色固体，mp:126.5–127.9℃。
1H NMR(400MHz,CDCl3)δ7.24(d,J＝7.8Hz,2H),7.20(d,J＝7.1Hz,1H),7.10(t,J＝7.4Hz,2H),7.03(d,J＝8.0Hz,2H),6.93(d,J＝7.9Hz,2H),5.76(s,1H),4.35(d,J＝7.1Hz,1H),3.49(s,3H),2.71(dt,J＝10.8,5.1Hz,1H),2.63–2.52(m,2H),2.51–2.30(m,4H),2.29–2.16(m,4H),2.07–1.93(m,3H),1.90(s,3H),1.79–1.66(m,2H),1.51–1.41(m,1H),1.37–1.28(m,1H),0.40(s,3H).
13C NMR(101MHz,CDCl3)δ199.44,170.57,156.56,145.35,143.47,142.60,135.78,129.69,129.67,128.87,127.81,127.61,127.09,123.16,82.66,82.28,80.06,49.67,46.93,40.09,39.34,39.17,38.90,38.22,36.80,31.13,27.38,25.80,23.39,13.75,3.90.
HRMS(ESI-TOF):calcd for C35H36NO3[M-H]-518.2701；found 519.2693.
实施例15
3-Chloro-N-(4-((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-(prop-1-yn-1-yl)-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-11-yl)phenyl)-N-methylpropanamide(FZU-0002-014)
与实施例14不同之处在于：将44mg,0.36mmol的吡啶甲酸替换为39mg,0.36mmol3-氯丙酸，得到147mg产物，产率为97％，PE/EtOAc＝1:1，产物为白色固体。
1H NMR(400MHz,CDCl3)δ7.26(d,J＝8.2Hz,2H),7.11(d,J＝8.4Hz,2H),5.80(s,1H),4.47(d,J＝7.0Hz,1H),3.80–3.67(m,2H),3.27(s,3H),2.81(dt,J＝10.1,5.6Hz,1H),2.65–2.57(m,2H),2.54–2.41(m,5H),2.37–2.22(m,3H),2.09–2.02(m,1H),2.01–1.92(m,1H),1.90(s,3H),1.79–1.71(m,2H),1.52–1.46(m,1H),1.40–1.31(m,1H),0.51(s,3H).
13C NMR(101MHz,CDCl3)δ199.33,169.64,156.47,145.11,145.00,141.08,129.91,128.58,127.44,123.32,82.71,82.30,80.06,49.82,47.00,40.21,40.16,39.28,39.18,39.00,37.40,36.96,36.85,31.14,27.39,26.01,23.42,13.95,3.92.
HRMS(ESI-TOF):calcd for C31H35ClNO3[M-H]-504.2311；found 504.2322.
实施例16
4-Chloro-N-(4-((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-(prop-1-yn-1-yl)-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-11-yl)phenyl)-N-methylbenzamide(FZU-0002-015)
与实施例14不同之处在于：将吡啶甲酸替换为4-氯苯甲酸，得到140mg产物，产率为90％，产物为白色固体，mp:117.4–118.6℃。
1H NMR(400MHz,CDCl3)δ7.18(d,J＝8.5Hz,2H),7.12–6.99(m,4H),6.92(d,J＝8.4Hz,2H),5.77(s,1H),4.37(d,J＝7.1Hz,1H),3.46(s,3H),2.73(dt,J＝15.0,5.3Hz,1H),2.63–2.49(m,2H),2.49–2.29(m,4H),2.28–2.17(m,3H),2.09–1.92(m,3H),1.89(s,3H),1.80–1.66(m,2H),1.53–1.39(m,1H),1.37–1.26(m,1H),0.37(s,3H).
13C NMR(101MHz,CDCl3)δ199.36,169.41,156.48,145.13,143.82,142.36,135.76,134.23,130.39,129.80,128.01,127.92,127.09,123.27,82.74,82.26,80.09,49.72,46.99,40.10,39.39,39.15,38.98,38.32,36.82,31.15,27.41,25.88,23.41,13.76,3.93.
HRMS(ESI-TOF):calcd for C35H35ClNO3[M-H]-552.2311；found 552.2292.
实施例17
3-Chloro-N-(4-((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-(prop-1-yn-1-yl)-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-11-yl)phenyl)-N,4-dimethylbenzamide(FZU-0010-021)
与实施例13不同之处在于：将37mg,0.3mmol的吡啶甲酸替换为51mg,0.3mmol4-甲基-3-氯苯甲酸，PE/EtOAc＝3:2，得到产物为70mg,得率为61％。产物为白色固体，mp:116.6–117.8℃。
1H NMR(400MHz,CDCl3)δ7.24(s,1H),7.07(d,J＝8.3Hz,2H),7.03(dd,J＝7.9,1.6Hz,1H),7.01–6.87(m,4H),5.77(s,1H),4.37(d,J＝7.3Hz,1H),3.47(s,3H),2.77–2.66(m,1H),2.63–2.53(m,2H),2.49–2.36(m,3H),2.36–2.31(m,1H),2.30–2.25(m,3H),2.23–2.14(m,3H),2.07–1.96(m,2H),1.91(s,3H),1.80–1.68(m,2H),1.53–1.43(m,1H),1.38–1.29(m,1H),0.44(s,3H).
13C NMR(101MHz,CDCl3)δ199.40,169.01,156.53,145.29,143.84,142.39,137.95,134.83,133.71,130.12,129.77,129.67,128.03,127.25,127.02,123.21,82.69,82.30,80.09,49.64,46.94,40.18,39.37,39.28,38.94,38.38,36.81,31.18,27.44,25.85,23.42,20.03,13.75,3.90.
实施例18
N-(4-((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-(prop-1-yn-1-yl)-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-11-yl)phenyl)-3-methoxy-N-methylbenzamide(FZU-0010-022)
与实施例17不同之处在于：将51mg,0.3mmol4-甲基-3-氯苯甲酸替换为61mg,0.3mmol的3-甲氧基苯甲酸，得到76mg的产物，得率为69％，产物为白色固体，mp:112.6–113.8℃。
1H NMR(400MHz,CDCl3)δ7.09–7.01(m,2H),7.00–6.91(m,3H),6.88(s,1H),6.75(d,J＝7.7Hz,2H),5.76(s,1H),4.35(d,J＝6.5Hz,1H),3.67(s,3H),3.48(s,3H),2.78–2.64(m,1H),2.62–2.51(m,2H),2.50–2.30(m,4H),2.28–2.16(m,3H),2.11–1.94(m,3H),1.86(s,3H),1.81–1.65(m,2H),1.53–1.40(m,1H),1.37–1.28(m,1H),0.41(s,3H).
13C NMR(101MHz,CDCl3)δ199.42,170.40,158.97,156.56,145.38,143.52,142.61,137.09,129.71,128.60,127.83,126.96,123.17,121.27,115.66,114.12,82.67,82.30,80.08,55.22,49.66,46.91,40.15,39.36,39.25,38.92,38.24,36.81,31.16,27.41,25.82,23.41,13.68,3.89.
HRMS(ESI-TOF):calcd for C36H40NO4[M+H]+550.2952；found 550.2945.
实施例19
4-Chloro-N-(4-((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-(prop-1-yn-1-yl)-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-11-yl)phenyl)-N-methyl-2-nitrobenzamide(FZU-0010-023)
与实施例17不同之处在于：将51mg,0.3mmol的4-甲基-3-氯苯甲酸替换为80mg,0.4mmol的4-氯-2-硝基苯甲酸，PE/EtOAc＝1:1得到81mg的产物，得率为68％，产物为白色固体，mp:128.5–129.6℃。
1H NMR(400MHz,CDCl3)δ7.81(d,J＝1.5Hz,1H),7.40(dd,J＝8.2,1.5Hz,1H),7.22(d,J＝8.2Hz,1H),6.95(q,J＝8.4Hz,4H),5.73(s,1H),4.29(d,J＝7.0Hz,1H),3.47(s,3H),2.72–2.61(m,1H),2.57–2.48(m,2H),2.45–2.23(m,6H),2.21–2.05(m,3H),2.05–1.95(m,1H),1.95–1.87(m,1H),1.82(s,3H),1.76–1.60(m,2H),1.49–1.37(m,1H),1.33–1.24(m,1H),0.20(s,3H).13C NMR(101MHz,CDCl3)δ199.22,166.14,156.40,146.22,144.89,144.86,140.11,135.18,133.36,131.65,130.55,129.70,128.00,127.02,124.20,123.13,82.43,82.19,76.84,49.53,46.76,39.97,39.24,38.98,38.81,37.00,36.66,31.00,27.26,25.70,23.28,13.35,3.79.
HRMS(ESI-TOF):calcd for C35H36ClN2O5[M+H]+599.2307；found 599.2294.
实施例20
3,5-Dichloro-N-(4-((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-(prop-1-yn-1-yl)-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-11-yl)phenyl)-N-methylbenzamide(FZU-0010-024)
与实施例19不同之处在于：将80mg,0.4mmol的4-氯-2-硝基苯甲酸替换为76mg,0.4mmol3,5-二氯苯甲酸，得到73mg的产物，得率为61％。产物为白色固体，mp:115.7–116.9℃。
1H NMR(400MHz,CDCl3)δ7.19(t,J＝1.8Hz,1H),7.14–7.09(m,2H),7.08(d,J＝8.3Hz,2H),6.92(d,J＝8.4Hz,2H),5.75(s,1H),4.35(d,J＝7.2Hz,1H),3.44(s,3H),2.75–2.62(m,1H),2.59–2.48(m,2H),2.48–2.26(m,4H),2.24–2.07(m,3H),2.07–1.95(m,2H),1.88(s,3H),1.77–1.62(m,2H),1.52–1.39(m,1H),1.37–1.26(m,1H),0.44(s,3H).
13C NMR(101MHz,CDCl3)δ199.33,167.50,156.45,145.03,144.32,141.71,138.64,134.49,129.86,129.72,128.24,127.40,126.99,123.30,82.71,82.29,80.11,49.66,46.90,40.16,39.23,38.95,38.39,36.82,31.20,27.45,25.86,23.40,13.79,3.92.
HRMS(ESI-TOF):calcd for C35H36Cl2NO3[M+H]+588.2067；found 588.2058.
实施例21
N-(4-((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-(prop-1-yn-1-yl)-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-11-yl)phenyl)-2-methoxy-N-methylbenzamide(FZU-0010-026)
与实施例20不同之处在于：将76mg,0.4mmol3,5-二氯苯甲酸替换为61mg,0.3mmol的甲氧基苯甲酸，PE/EtOAc＝2:3，得到75mg的产物，得率为68％。产物为白色固体，mp:124.2–125.3℃。
1H NMR(400MHz,CDCl3)δ7.19–7.05(m,2H),7.03–6.87(m,4H),6.74(t,J＝7.1Hz,1H),6.57(d,J＝8.3Hz,1H),5.75(s,1H),4.29(d,J＝6.7Hz,1H),3.61(s,3H),3.46(s,3H),2.77–2.62(m,1H),2.60–2.49(m,2H),2.49–2.27(m,4H),2.27–2.08(m,4H),2.03–1.91(m,2H),1.87(s,3H),1.79–1.61(m,2H),1.51–1.39(m,1H),1.36–1.27(m,1H),0.29(s,3H).
13C NMR(101MHz,CDCl3)δ199.42,169.31,156.55,155.11,145.48,143.39,141.69,130.28,129.64,128.72,127.00,126.85,126.59,123.11,120.16,110.48,82.66,82.27,80.06,55.16,49.63,46.81,40.12,39.28,39.21,38.90,36.92,36.82,31.13,27.39,25.80,23.39,13.56,3.87.
HRMS(ESI-TOF):calcd for C36H40NO4[M+H]+550.2952；found 550.2942.
实施例22
4-Chloro-N-(4-((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-(prop-1-yn-1-yl)-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-11-yl)phenyl)-N-methyl-3-nitrobenzamide(FZU-0010-027)
与实施例20不同之处在于：将76mg,0.4mmol3,5-二氯苯甲酸替换为81mg,0.4mmol的4-氯-3-硝基苯甲酸，得到90mg的产物，得率为74％。产物为白色固体，mp:123.3–124.6℃℃℃℃。
1H NMR(400MHz,CDCl3)δ7.78(s,1H),7.41(d,J＝8.3Hz,1H),7.30(d,J＝8.7Hz,1H),7.13(d,J＝7.9Hz,2H),6.97(d,J＝7.8Hz,2H),5.78(s,1H),4.38(d,J＝7.0Hz,1H),3.49(s,3H),2.81–2.68(m,1H),2.64–2.53(m,2H),2.51–2.30(m,4H),2.29–2.14(m,3H),2.09–1.98(m,2H),1.98–1.91(m,1H),1.87(s,3H),1.79–1.65(m,2H),1.55–1.41(m,1H),1.38–1.25(m,1H),0.38(s,3H).
13C NMR(101MHz,CDCl3)δ199.32,166.68,156.39,147.10,144.73,144.66,141.52,135.61,133.33,131.28,129.95,128.45,128.38,127.08,126.33,123.36,82.74,82.19,80.04,49.68,46.95,40.05,39.25,39.08,38.98,38.55,36.79,31.14,27.39,25.87,23.37,13.69,3.94.
HRMS(ESI-TOF):calcd for C35H35ClN2NaO5[M+Na]+621.2127；found 621.2166.
实施例23
4-Chloro-3-fluoro-N-(4-((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-(prop-1-yn-1-yl)-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-11-yl)phenyl)-N-methylbenzamide(FZU-0010-028)
与实施例22不同之处在于：81mg,0.4mmol的4-氯-3-硝基苯甲酸为52mg,0.3mmol的3-氯-4-氟苯甲酸，得到75mg的产物，得率为64％。产物为白色固体，mp:121.2–122.2℃。
1H NMR(400MHz,CDCl3)δ7.13(d,J＝7.8Hz,1H),7.11–7.06(m,2H),7.04(dd,J＝9.5,1.5Hz,1H),6.95(dd,J＝11.9,9.3Hz,3H),5.77(s,1H),4.37(d,J＝7.1Hz,1H),3.45(d,J＝8.8Hz,3H),2.73(dt,J＝14.9,5.2Hz,1H),2.65–2.53(m,2H),2.52–2.29(m,4H),2.28–2.17(m,3H),2.17–2.08(m,1H),2.08–1.93(m,2H),1.89(s,3H),1.80–1.64(m,2H),1.53–1.41(m,1H),1.38–1.29(m,1H),0.37(s,3H).
13C NMR(101MHz,CDCl3)δ199.27,168.00,158.48,156.41,155.99,145.02,144.21,141.96,136.17,136.11,129.89,129.81,128.16,127.00,125.47,125.43,123.26,122.71,122.53,117.44,117.21,82.63,82.27,80.04,49.68,46.94,40.10,39.35,39.13,38.97,38.34,36.78,31.13,27.39,25.85,23.38,13.62,3.90.
HRMS(ESI-TOF):calcd for C35H36ClFNO3[M+H]+572.2362；found 572.2355.
实施例24
3-Chloro-N-(4-((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-(prop-1-yn-1-yl)-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-11-yl)phenyl)-N-methyl-2-nitrobenzamide(FZU-0010-029)
与实施例22不同之处在于：4-氯-3-硝基苯甲酸为60mg,0.3mmol，得到74mg的产物，得率为61％。产物为白色固体，mp:121.8–123.0℃。
1H NMR(400MHz,CDCl3)δ7.34(d,J＝8.0Hz,1H),7.15(d,J＝7.9Hz,2H),7.11–6.95(m,3H),6.87(d,J＝7.6Hz,1H),5.77(s,1H),4.36(d,J＝7.0Hz,1H),3.46(s,3H),2.82–2.66(m,1H),2.65–2.53(m,2H),2.50–2.28(m,4H),2.26–2.11(m,3H),2.09–1.99(m,2H),1.97–1.91(m,1H),1.89(s,3H),1.80–1.63(m,2H),1.53–1.41(m,1H),1.35–1.20(m,1H),0.31(s,3H).
13C NMR(101MHz,CDCl3)δ199.38,165.01,156.50,147.52,144.98,144.79,140.82,133.13,131.42,130.31,129.85,128.27,127.52,126.75,126.48,123.28,82.84,82.17,80.05,49.65,46.93,40.12,39.42,39.17,38.89,37.57,36.81,31.15,27.40,25.85,23.38,13.68,3.92.
实施例25
3-Chloro-4-fluoro-N-(4-((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-(prop-1-yn-1-yl)-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-11-yl)phenyl)-N-methylbenzamide(FZU-0010-030)
与实施例23不同之处在于：3-氯-4-氟苯甲酸为70mg,0.4mmol，得到80mg的产物，得率为68％。产物为白色固体，mp:118.6–119.6℃。
1H NMR(400MHz,CDCl3)δ7.35(dd,J＝7.0,2.1Hz,1H),7.16–7.11(m,1H),7.09(d,J＝8.3Hz,2H),6.94(d,J＝8.4Hz,2H),6.86(t,J＝8.6Hz,1H),5.77(s,1H),4.38(d,J＝7.1Hz,1H),3.46(s,3H),2.73(dt,J＝14.8,5.2Hz,1H),2.64–2.53(m,2H),2.51–2.30(m,4H),2.28–2.16(m,4H),2.08–1.98(m,2H),1.91(s,3H),1.81–1.67(m,2H),1.51–1.41(m,1H),1.39–1.30(m,1H),0.43(s,3H).
13C NMR(101MHz,CDCl3)δ199.38,167.98,159.84,157.33,156.53,145.10,144.04,142.12,132.82,132.78,131.74,129.79,129.26,129.19,128.13,126.98,123.23,120.66,120.48,115.92,115.71,82.64,82.28,80.04,49.69,46.95,40.09,39.29,39.14,38.95,38.47,36.77,31.14,27.38,25.84,23.37,13.80,3.89.
HRMS(ESI-TOF):calcd for C35H36ClFNO3[M+H]+572.2362；found 572.2355.
实施例26
4-Chloro-N-(4-((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-(prop-1-yn-1-yl)-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-11-yl)phenyl)-2-methoxy-N-methylbenzamide(FZU-0010-032)
与实施例25不同之处在于：将70mg,0.4mmol的3-氯-4-氟苯甲酸替换为75mg,0.4mmol的2-氯-4-甲氧基苯甲酸，得到82mg的产物，得率为69％。产物为白色固体,mp:122.6–123.8℃。
1H NMR(400MHz,CDCl3)δ7.05(d,J＝7.8Hz,1H),7.00–6.83(m,4H),6.74(d,J＝7.7Hz,1H),6.57(s,1H),5.77(s,1H),4.32(d,J＝6.4Hz,1H),3.62(s,3H),3.45(s,3H),2.76–2.63(m,1H),2.62–2.51(m,2H),2.50–2.28(m,4H),2.27–2.12(m,3H),2.09–1.96(m,2H),1.96–1.92(m,1H),1.89(s,3H),1.79–1.65(m,2H),1.53–1.40(m,1H),1.38–1.27(m,1H),0.29(s,3H).
13C NMR(101MHz,CDCl3)δ199.37,168.26,156.53,155.82,145.26,143.71,141.40,135.71,129.71,129.60,127.17,126.84,125.27,123.18,120.34,111.31,82.65,82.22,80.06,55.49,49.67,46.86,40.09,39.32,39.15,38.98,36.96,36.81,31.13,27.39,25.85,23.39,13.56,3.89.
HRMS(ESI-TOF):calcd for C36H39ClNO4[M+H]+584.2562；found 584.2544.
实施例27
3-Bromo-4-chloro-N-(4-((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-(prop-1-yn-1-yl)-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-11-yl)phenyl)-N-methylbenzamide(FZU-0010-036)
与实施例25不同之处在于：将70mg,0.4mmol的3-氯-4-氟苯甲酸替换为71mg,0.3mmol的3-溴-4-氯苯甲酸，得到84mg的产物，得率为66％。产物为白色固体。
1H NMR(400MHz,CDCl3)δ7.55(s,1H),7.18(d,J＝8.3Hz,1H),7.12(s,1H),7.10(d,J＝8.1Hz,2H),6.94(d,J＝8.1Hz,2H),5.78(s,1H),4.38(d,J＝7.2Hz,1H),3.46(s,3H),2.73(dt,J＝14.9,5.1Hz,1H),2.65–2.55(m,2H),2.52–2.31(m,4H),2.29–2.17(m,3H),2.08–1.92(m,3H),1.90(s,3H),1.80–1.65(m,2H),1.54–1.42(m,1H),1.39–1.28(m,1H),0.44(s,3H).
13C NMR(101MHz,CDCl3)δ199.33,167.82,156.46,145.00,144.14,141.96,135.97,135.65,134.30,129.85,129.52,128.90,128.18,127.02,123.30,121.90,82.74,82.24,80.09,49.68,46.97,40.11,39.31,39.17,38.97,38.43,36.83,31.18,27.43,25.91,23.40,13.90,3.95.
HRMS(ESI-TOF):calcd for C35H36BrClNO3[M+H]+632.1562；found 632.1559.
实施例28
2-Bromo-4-chloro-N-(4-((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-(prop-1-yn-1-yl)-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-11-yl)phenyl)-N-methylbenzamide(FZU-0010-037)
与实施例27不同之处在于：将3-溴-4-氯苯甲酸替换为2-溴-4-氯苯甲酸，得到68mg的产物，得率为54％。产物为白色固体，mp:128.8–129.9℃。
1H NMR(400MHz,CDCl3)δ7.37(s,1H),7.10–6.84(m,6H),5.77(s,1H),4.32(d,J＝7.0Hz,1H),3.48(s,3H),2.77–2.64(m,1H),2.63–2.54(m,2H),2.50–2.27(m,5H),2.26–2.12(m,3H),2.10–1.98(m,3H),1.97–1.92(m,1H),1.88(s,3H),1.79–1.60(m,2H),1.52–1.39(m,1H),1.36–1.24(m,1H),0.22(s,3H).
13C NMR(101MHz,CDCl3)δ199.37,168.05,156.48,145.07,144.45,140.64,137.09,134.86,132.26,129.78,127.72,126.98,126.93,123.24,120.42,82.66,82.19,80.04,49.65,46.82,40.05,39.36,39.07,38.97,36.98,36.78,31.12,27.37,25.83,23.38,13.39,3.92.
实施例29
5-Chloro-2-fluoro-N-(4-((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-(prop-1-yn-1-yl)-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-11-yl)phenyl)-N-methylbenzamide(FZU-0010-038)
将105mg,0.6mmol的4-氯-2-氟苯甲酸、84mg,0.2mmol的美她司酮和192mg,1.0mmol的EDCI加入到2.0mL的CH2Cl2中，搅拌30小时，用方法C制备，PE/EtOAc＝2:1，得到70mg的产物，得率为61％。产物为白色固体，mp:121.5–122.7℃。
1H NMR(400MHz,CDCl3)δ7.23(d,J＝2.8Hz,1H),7.16–7.09(m,1H),7.03(d,J＝8.1Hz,2H),6.97(d,J＝8.0Hz,2H),6.69(t,J＝8.7Hz,1H),5.77(s,1H),4.34(d,J＝7.0Hz,1H),3.47(s,3H),2.75–2.64(m,1H),2.63–2.52(m,2H),2.49–2.29(m,4H),2.27–2.12(m,3H),2.09–1.98(m,2H),1.97–1.92(m,1H),1.89(s,3H),1.81–1.66(m,2H),1.53–1.40(m,1H),1.36–1.25(m,1H),0.31(s,3H).
13C NMR(101MHz,CDCl3)δ199.36,165.18,157.71,156.49,155.23,145.17,144.44,140.66,130.95,130.87,129.78,129.31,129.13,127.72,127.08,126.78,126.59,123.23,116.99,116.76,82.71,82.26,80.07,49.67,46.85,40.15,39.39,39.19,38.92,37.36,36.82,31.15,27.41,25.82,23.40,13.44,3.89.
HRMS(ESI-TOF):calcd for C35H36ClFNO3[M+H]+572.2362；found 572.2358.
实施例30
3-Chloro-N-(4-((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-(prop-1-yn-1-yl)-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-11-yl)phenyl)-4-methoxy-N-methylbenzamide(FZU-0010-039)
与实施例28不同之处在于：将71mg,0.3mmol的2-溴-4-氯苯甲酸替换为56mg,0.3mmol的4-氯-3-甲氧基苯甲酸，得到86mg的产物，得率为73％，产物为白色固体，mp:122.1–123.4℃。
1H NMR(400MHz,CDCl3)δ7.30(s,1H),7.14(d,J＝8.5Hz,1H),7.07(d,J＝7.9Hz,2H),6.94(d,J＝7.7Hz,2H),6.62(d,J＝8.5Hz,1H),5.76(s,1H),4.37(d,1H),3.82(s,3H),3.46(s,3H),2.80–2.67(m,1H),2.63–2.52(m,2H),2.50–2.29(m,4H),2.28–2.17(m,3H),2.07–1.91(m,3H),1.89(s,3H),1.80–1.65(m,2H),1.54–1.41(m,1H),1.40–1.28(m,1H),0.46(s,3H).
13C NMR(101MHz,CDCl3)δ199.42,168.73,156.57,155.99,145.23,143.64,142.64,131.31,129.76,129.31,128.57,128.01,126.96,123.20,121.60,110.63,82.67,82.25,80.05,56.18,49.64,46.94,40.10,39.33,39.22,38.92,38.47,36.79,31.17,27.41,25.84,23.40,13.91,3.91.
HRMS(ESI-TOF):calcd for C36H39ClNO4[M+H]+584.2562；found 584.2559.
实施例31
4-Chloro-N-(4-((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-(prop-1-yn-1-yl)-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-11-yl)phenyl)-N-methyl-3-(trifluoromethyl)benzamide(FZU-0010-041)
与实施例30的不同之处在于：将56mg,0.3mmol的4-氯-3-甲氧基苯甲酸替换为67mg,0.3mmol的4-氯-3-三氟甲基苯甲酸，得到84mg的产物，得率为62％，产物为白色固体，mp:205.3–206.2℃。
1H NMR(400MHz,CDCl3)δ7.61(s,1H),7.38(d,J＝8.3Hz,1H),7.27(dd,J＝11.4,4.6Hz,1H),7.10(d,J＝8.2Hz,2H),6.94(d,J＝8.0Hz,2H),5.77(s,1H),4.37(d,J＝7.1Hz,1H),3.48(s,3H),2.71(dt,J＝14.9,5.2Hz,1H),2.62–2.52(m,2H),2.51–2.30(m,4H),2.26–2.17(m,3H),2.15–2.08(m,1H),2.07–1.92(m,2H),1.88(s,3H),1.79–1.62(m,2H),1.54–1.41(m,1H),1.38–1.26(m,1H),0.41(s,3H).
13C NMR(101MHz,CDCl3)δ199.28,167.79,156.42,144.87,144.27,141.86,134.60,133.73,133.28,130.88,129.87,128.40,128.35,128.25,127.98,127.66,127.02,123.73,123.30,121.01,82.65,82.26,80.02,49.69,46.94,40.07,39.22,39.08,38.97,38.51,36.77,31.12,27.39,25.82,23.36,13.72,3.88.
HRMS(ESI-TOF):calcd for C36H36ClF3NO3[M+H]+622.2330；found 622.2323.
实施例32
N-(4-((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-(prop-1-yn-1-yl)-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-11-yl)phenyl)-N-methylthiazole-2-carboxamide(FZU-0010-048)
与实施例30的不同之处在于：将56mg,0.3mmol的4-氯-3-甲氧基苯甲酸替换为39mg,0.3mmol的噻唑-2-甲酸，得到70mg的产物，得率为66％，产物为白色固体，mp:194.8–195.9℃。
1H NMR(400MHz,CDCl3)δ7.63–7.43(m,1H),7.40–7.30(m,1H),7.22–6.98(m,4H),5.77(s,1H),4.43(d,J＝7.1Hz,1H),3.51(s,3H),2.77(dt,J＝10.5,5.7Hz,1H),2.63–2.54(m,2H),2.51–2.39(m,3H),2.38–2.34(m,1H),2.34–2.24(m,3H),2.24–2.18(m,2H),2.07–1.94(m,2H),1.88(s,3H),1.81–1.69(m,2H),1.54–1.42(m,1H),1.39–1.29(m,1H),0.52(s,3H).
13C NMR(101MHz,CDCl3)δ199.42,161.12,156.59,145.48,144.37,143.00,141.64,129.67,127.91,127.18,123.11,82.58,82.32,80.02,49.71,46.98,40.20,39.30,39.17,38.88,36.81,31.11,27.34,25.85,23.37,13.86,3.89.
HRMS(ESI-TOF):calcd for C32H35N2O3S[M+H]+527.2363；found 527.2354.
实施例33
N-(4-((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-(prop-1-yn-1-yl)-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-11-yl)phenyl)-N-methylthiazole-5-carboxamide(FZU-0010-049)
与实施例32的不同之处在于：将噻唑-2-甲酸替换为噻唑-5-甲酸，PE/EtOAc＝1:2，得到78mg的产物，得率为74％，产物为白色固体，mp:123.5–124.7℃。
1H NMR(400MHz,CDCl3)δ8.65(s,1H),7.52(s,1H),7.27(d,J＝8.0Hz,2H),7.15(d,J＝7.8Hz,2H),5.79(s,1H),4.48(d,J＝7.1Hz,1H),3.43(s,3H),2.88–2.75(m,1H),2.66–2.56(m,2H),2.53–2.43(m,3H),2.41–2.36(m,1H),2.37–2.21(m,4H),2.17–2.08(m,1H),2.08–1.99(m,2H),1.98–1.93(m,1H),1.89(s,3H),1.81–1.68(m,2H),1.56–1.44(m,1H),1.40–1.31(m,1H),0.58(s,3H).
13C NMR(101MHz,CDCl3)δ199.39,161.18,156.69,156.48,147.44,146.23,144.92,140.84,133.32,129.97,128.83,128.26,123.33,82.63,82.25,80.02,49.66,47.11,40.29,39.46,39.25,38.99,38.74,36.80,31.16,27.40,25.93,23.41,14.44,3.93.
HRMS(ESI-TOF):calcd for C32H35N2O3S[M+H]+527.2363；found 527.2355.
实施例34
N-(4-((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-(prop-1-yn-1-yl)-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-11-yl)phenyl)-N-methylpyrazine-2-carboxamide(FZU-0010-050)
与实施例33不同之处在于：将39mg,0.3mmol的噻唑-5-甲酸替换为50mg,0.4mmol的吡嗪-2-羧酸，得到72mg的产物，得率为69％，产物为白色固体，mp:116.5–117.7℃。
1H NMR(400MHz,CDCl3)δ8.69(s,1H),8.38(s,1H),8.21(s,1H),7.18–6.87(m,4H),5.77(s,1H),4.35(d,J＝6.5Hz,1H),3.52(s,3H),2.80–2.67(m,1H),2.66–2.51(m,2H),2.51–2.30(m,5H),2.26–2.13(m,3H),2.10–1.93(m,3H),1.84(s,3H),1.79–1.63(m,2H),1.52–1.40(m,1H),1.36–1.24(m,1H),0.36(s,3H).
13C NMR(101MHz,CDCl3)δ199.39,166.49,156.52,149.87,145.13,144.91,144.50,144.11,142.83,141.29,129.74,127.92,127.15,123.20,82.66,82.24,79.98,49.66,46.90,40.04,39.27,39.12,38.89,37.87,36.79,31.10,27.33,25.83,23.36,13.71,3.90.
HRMS(ESI-TOF):calcd for C33H36N3O3[M+H]+522.2751；found 522.2741.
实施例35
N-(4-((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-(prop-1-yn-1-yl)-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-11-yl)phenyl)-N-methylthiophene-2-carboxamide(FZU-0010-051)
与实施例34不同之处在于：将50mg,0.4mmol的吡嗪-2-羧酸替换为51mg,0.4mmol的噻吩-2-羧酸，得到70mg的产物，得率为66％，产物为白色固体，mp:124.9–126.2℃。
1H NMR(400MHz,CDCl3)δ7.27(dd,J＝7.3,5.9Hz,1H),7.25–7.19(m,2H),7.16(d,J＝8.5Hz,2H),6.77–6.61(m,2H),5.79(s,1H),4.48(d,J＝7.2Hz,1H),3.43(s,3H),2.80(dt,J＝10.3,5.8Hz,1H),2.66–2.56(m,2H),2.53–2.42(m,3H),2.42–2.36(m,1H),2.34–2.16(m,4H),2.10–2.01(m,1H),1.99–1.94(m,1H),1.91(s,3H),1.83–1.69(m,2H),1.58–1.44(m,1H),1.41–1.33(m,1H),0.59(s,3H).
13C NMR(101MHz,CDCl3)δ199.29,162.78,156.45,145.46,145.16,141.86,138.10,132.26,130.52,129.87,128.52,128.25,126.53,123.29,82.75,82.31,80.08,49.71,47.13,40.33,39.54,39.30,38.95,38.91,36.85,31.19,27.45,25.93,23.45,14.16,3.93.
实施例36
4-((4-((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-(prop-1-yn-1-yl)-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-11-yl)phenyl)(methyl)amino)-4-oxobutanoic acid(FZU-0002-013)
与实施例34不同之处在于：将50mg,0.4mmol的吡嗪-2-羧酸替换为47mg，0.4mmol的丁二酸，根据方法c.得到100mg白色固体，收率67％。
1H NMR(400MHz,CDCl3)δ7.25(d,J＝8.2Hz,2H),7.13(d,J＝8.4Hz,2H),5.81(s,1H),4.46(d,J＝7.0Hz,1H),3.25(s,3H),2.88–2.75(m,1H),2.69–2.52(m,4H),2.51–2.37(m,4H),2.37–2.15(m,5H),2.10–1.92(m,2H),1.91(s,3H),1.81–1.67(m,2H),1.55–1.44(m,1H),1.39–1.32(m,1H),0.46(s,3H).
13C NMR(101MHz,CDCl3)δ199.82,172.17,156.92,145.45,145.01,141.14,129.85,128.60,127.33,123.20,82.71,82.23,80.13,49.78,47.00,40.25,39.22,38.93,37.58,36.75,31.16,29.71,29.17,27.37,25.96,23.41,13.96,3.94.
HRMS(ESI-TOF):calcd for C32H36NO5[M-H]-514.2599；found 514.2576.
实施例37
2-Chloro-N-(4-((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-(prop-1-yn-1-yl)-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-11-yl)phenyl)-N-methylbenzamide(FZU-0002-017)
与实施例34不同之处在于：将50mg,0.4mmol的吡嗪-2-羧酸替换为56mg，0.36mmol邻氯苯甲酸，根据方法c得到140mg白色固体，收率84％。
1H NMR(400MHz,CDCl3)δ7.48–7.33(m,1H),7.15(d,J＝7.8Hz,1H),7.10–7.04(m,2H),7.03–6.92(m,4H),5.76(s,1H),4.30(d,J＝7.2Hz,1H),3.49(s,3H),2.66(dt,J＝14.9,5.4Hz,1H),2.60–2.53(m,2H),2.47–2.26(m,4H),2.25–2.09(m,3H),2.02–1.97(m,2H),1.88(s,3H),1.77–1.64(m,2H),1.49–1.38(m,1H),1.32–1.27(m,1H),0.22(s,3H).
13C NMR(101MHz,CDCl3)δ199.40,168.28,156.51,145.30,144.19,140.87,136.53,130.65,129.70,129.36,128.83,127.56,126.95,126.10,123.16,82.65,82.24,80.04,49.61,46.77,40.09,39.33,39.15,38.87,38.69,36.92,36.79,31.12,27.37,25.76,23.37,13.38,3.89.
HRMS(ESI-TOF):calcd for C35H35ClNO3[M-H]-552.2311；found 552.2294.
实施例38
N-(4-((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-(prop-1-yn-1-yl)-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-11-yl)phenyl)-4-methoxy-N-methylbenzamide(FZU-0010-016)
与实施例34不同之处在于：将50mg,0.4mmol的吡嗪-2-羧酸替换为63mg，0.36mmol对甲氧基苯甲酸，根据方法c得到120mg白色固体，收率70％，mp:114.2–115.6℃。
1H NMR(400MHz,CDCl3)δ7.21(d,J＝8.4Hz,2H),7.05(d,J＝8.0Hz,2H),6.94(d,J＝8.1Hz,2H),6.60(d,J＝8.5Hz,2H),5.77(s,1H),4.37(d,J＝6.9Hz,1H),3.72(s,3H),3.46(s,3H),2.83–2.70(m,1H),2.63–2.53(m,2H),2.50–2.33(m,2H),2.31–2.18(m,2H),2.16–2.10(m,1H),2.08–1.94(m,3H),1.90(s,3H),1.79–1.67(m,2H),1.50–1.42(m,1H),1.39–1.30(m,1H),0.42(s,3H).
13C NMR(101MHz,CDCl3)δ199.45,170.12,160.62,156.60,145.38,143.26,143.10,131.09,129.71,127.86,127.77,127.00,123.18,112.84,82.70,82.28,80.07,55.28,49.70,46.97,40.11,39.40,39.21,38.92,38.45,36.81,31.16,27.41,25.85,23.42,13.84,3.92.
HRMS(ESI-TOF):calcd for C36H40NO4[M+H]+550.2952；found 550.2950.
实施例39
4-Chloro-2,5-difluoro-N-(4-((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-(prop-1-yn-1-yl)-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-11-yl)phenyl)-N-methylbenzamide(FZU-0010-018)
与实施例34不同之处在于：将50mg,0.4mmol的吡嗪-2-羧酸替换为82mg，0.2mmol4-氯-2,5-二氟苯甲酸，根据方法c得到55mg白色固体，收率46％，mp:117.1–118.3℃。
1H NMR(400MHz,CDCl3)δ7.11–7.00(m,3H),6.96(d,J＝7.9Hz,2H),6.86–6.74(m,1H),5.78(s,1H),4.36(d,J＝7.0Hz,1H),3.46(s,3H),2.71(dt,J＝10.8,5.2Hz,1H),2.60–2.54(m,2H),2.49–2.29(m,4H),2.25–2.12(m,4H),2.01–1.91(m,2H),1.87(s,4H),1.80–1.67(m,2H),1.52–1.39(m,1H),1.36–1.28(m,1H),0.29(s,3H).
13C NMR(101MHz,CDCl3)δ199.31,164.45,156.44,145.00,144.65,140.47,129.84,127.81,127.08,123.29,117.88,117.61,116.90,116.65,82.69,82.24,80.04,49.71,46.89,40.11,39.42,39.12,38.97,37.37,36.80,31.14,27.40,25.87,23.39,13.35,3.90.
HRMS(ESI-TOF):calcd for C35H35ClF2NO3[M+H]+590.2268；found 590.2245.
实施例40
2,5-Dichloro-N-(4-((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-(prop-1-yn-1-yl)-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-11-yl)phenyl)-N-methylbenzamide(FZU-0010-020)
与实施例34不同之处在于：将50mg,0.4mmol的吡嗪-2-羧酸替换为152mg，0.08mmol的2,6-二氯苯甲酸，根据方法c.得到99mg黄色油状物，收率83％。
1H NMR(400MHz,CDCl3)δ7.22–6.94(m,7H),5.78(s,1H),4.34(d,J＝7.3Hz,1H),3.50(s,3H),2.69(dt,J＝15.0,5.4Hz,1H),2.63–2.57(m,2H),2.51–2.30(m,4H),2.29–2.19(m,2H),2.18–2.09(m,2H),2.08–2.00(m,1H),1.97(s,1H),1.91(s,3H),1.79–1.62(m,2H),1.52–1.42(m,1H),1.39–1.30(m,1H),0.28(s,3H).
13C NMR(101MHz,CDCl3)δ199.35,166.77,156.42,145.08,144.65,140.57,137.93,132.26,130.67,129.87,129.78,129.20,128.82,127.84,126.96,123.32,82.83,82.23,80.15,49.67,46.81,40.16,39.40,39.21,38.96,37.01,36.85,31.18,27.45,25.86,23.43,13.31,3.94.
HRMS(ESI-TOF):calcd for C35H36Cl2NO3[M+H]+588.2067；found 588.2058.
实施例41
5-Chloro-N-(4-((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-(prop-1-yn-1-yl)-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-11-yl)phenyl)-N,2-dimethylbenzamide(FZU-0010-025)
与实施例34不同之处在于：将50mg,0.4mmol的吡嗪-2-羧酸替换为51mg，0.3mmol的5-氯-2-甲基苯甲酸，得到63mg白色固体，收率55％，mp:125.4–126.8℃。
1H NMR(400MHz,CDCl3)δ7.13–6.98(m,3H),6.94–6.75(m,3H),5.77(s,1H),4.32(d,J＝5.6Hz,1H),3.49(s,3H),2.78–2.62(m,1H),2.62–2.54(m,2H),2.49–2.31(m,4H),2.27(s,3H),2.24–2.10(m,3H),2.07–1.95(m,3H),1.88(s,3H),1.79–1.63(m,2H),1.53–1.40(m,1H),1.37–1.25(m,1H),0.32(s,3H).
HRMS(ESI-TOF):calcd for C36H39ClNO3[M+H]+568.2613；found 568.2598.
实施例42
4-Chloro-2-fluoro-N-(4-((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-(prop-1-yn-1-yl)-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-11-yl)phenyl)-N-methylbenzamide(FZU-0010-031)
与实施例34不同之处在于：将50mg,0.4mmol的吡嗪-2-羧酸替换为70mg，0.4mmol的4-氯-2-氟苯甲酸，根据方法c.得到38mg白色固体，收率33％，mp:125.3–126.5℃℃。
1H NMR(400MHz,CDCl3)δ7.28(s,1H),7.23–7.14(m,1H),7.01(d,J＝8.6Hz,2H),6.96(d,J＝7.0Hz,2H),6.84–6.71(m,1H),5.78(d,J＝8.5Hz,1H),4.46–4.28(m,1H),3.62–3.36(m,3H),2.77–2.64(m,1H),2.62–2.52(m,2H),2.49–2.32(m,3H),2.26–2.11(m,3H),2.06–1.99(m,1H),1.89(s,3H),1.82–1.73(m,2H),1.52–1.40(m,1H),1.34–1.22(m,2H),0.93–0.76(m,2H),0.26(s,3H).
HRMS(ESI-TOF):calcd for C35H35ClFNO3[M+H]+572.2362；found 527.2356.
实施例43
2,4-Dichloro-N-(4-((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-(prop-1-yn-1-yl)-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-11-yl)phenyl)-N-methylbenzamide(FZU-0010-033)
与实施例34不同之处在于：将50mg,0.4mmol的吡嗪-2-羧酸替换为76mg，0.4mmol的2,4-二氯苯甲酸，根据方法c.得到71mg白色固体，收率60％，mp:121.5–122.6℃℃。
1H NMR(400MHz,CDCl3)δ7.37(s,1H),7.19(s,1H),7.02–6.98(m,5H),5.78(s,1H),4.33(s,1H),3.49(s,3H),2.77–2.64(m,1H),2.57–2.53(m,2H),2.49–2.28(m,4H),2.25–2.09(m,3H),2.08–1.98(m,1H),1.89(s,3H),1.82–1.66(m,3H),1.51–1.41(m,1H),1.32–1.21(m,1H),0.94–0.85(m,1H),0.23(s,3H).
HRMS(ESI-TOF):calcd for C35H36Cl2NO3[M+H]+588.2067；found 588.2059.
实施例44
3-Chloro-2-fluoro-N-(4-((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-(prop-1-yn-1-yl)-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-11-yl)phenyl)-N-methylbenzamide(FZU-0010-035)
与实施例34不同之处在于：将50mg,0.4mmol的吡嗪-2-羧酸替换为52mg，0.3mmol的2-氟，3-氯苯甲酸，根据方法c.得到130mg白色固体，收率80％，mp:123.5–124.5℃。
1H NMR(400MHz,CDCl3)δ7.23(t,J＝7.1Hz,1H),7.19–7.11(m,1H),7.10–6.88(m,5H),5.77(s,1H),4.33(d,J＝7.0Hz,1H),3.49(s,3H),2.77–2.63(m,1H),2.62–2.52(m,2H),2.48–2.31(m,4H),2.24–2.10(m,3H),2.06–1.92(m,3H),1.89(s,3H),1.76–1.62(m,2H),1.52–1.40(m,1H),1.39–1.28(m,1H),0.32(s,3H).
13C NMR(101MHz,CDCl3)δ199.40,165.61,156.49,145.17,144.45,140.69,131.46,129.82,127.72,127.15,126.86,126.68,124.52,123.27,82.76,82.27,80.14,49.67,46.84,40.17,39.34,39.22,38.96,37.37,36.84,31.18,27.44,25.83,23.42,13.46,3.91.
HRMS(ESI-TOF):calcd for C35H35ClFNO3[M+H]+572.2362；found 527.2359.
实施例45
4-(Dimethylamino)-N-(4-((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-(prop-1-yn-1-yl)-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-11-yl)phenyl)-N-methylbenzamide(FZU-0010-042)
与实施例34不同之处在于：将50mg,0.4mmol的吡嗪-2-羧酸替换为66mg，0.4mmol的4-二甲氨基苯甲酸，根据方法c.获得86mg白色固体，收率76％，mp:122.7–123.7℃。
1H NMR(400MHz,CDCl3)δ7.17(d,J＝8.9Hz,2H),7.06(d,J＝8.0Hz,2H),6.97(d,J＝8.4Hz,2H),6.36(d,J＝8.9Hz,2H),5.76(s,1H),4.38(s,1H),3.47(s,3H),2.90(s,6H),2.78–2.70(m,1H),2.61–2.53(m,2H),2.49–2.34(m,4H),2.28–2.17(m,3H),2.07–1.97(m,2H),1.90(s,3H),1.80–1.65(m,2H),1.54–1.41(m,1H),1.38–1.29(m,1H),0.91–0.86(m,1H),0.51(s,3H).
HRMS(ESI-TOF):calcd for C37H43N2O3[M+H]+563.3268；found 563.3261.
实施例46
3-(Dimethylamino)-N-(4-((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-(prop-1-yn-1-yl)-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-11-yl)phenyl)-N-methylbenzamide(FZU-0010-043)
与实施例34不同之处在于：将50mg,0.4mmol的吡嗪-2-羧酸替换为66mg，0.4mmol的3-二甲氨基苯甲酸，根据方法c.获得57mg白色固体，收率50％，mp:122.4–123.4℃。
1H NMR(400MHz,CDCl3)δ7.02–7.00(m,2H),6.98–6.96(s,2H),6.88(d,J＝6.2Hz,1H),6.74(s,1H),6.56(d,J＝4.4Hz,1H),6.44(d,J＝5.4Hz,1H),5.75(s,1H),4.33(s,1H),4.12(d,J＝6.8Hz,1H),3.47(s,3H),2.82(s,6H),2.72–2.68(m,1H),2.58–2.55(m,2H),2.37–2.34(m,4H),2.19–2.13(m,3H),1.99–1.96(m,1H),1.88(s,3H),1.73–1.70(m,2H),1.45–1.42(m,1H),1.32–1.28(m,1H),0.87–0.84(m,1H),0.42(s,3H).
HRMS(ESI-TOF):calcd for C37H43N2O3[M+H]+563.3268；found 563.3260.
实施例47
(E)-3-(4-(dimethylamino)phenyl)-N-(4-((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-(prop-1-yn-1-yl)-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-11-yl)phenyl)-N-methylacrylamide(FZU-0010-044)
与实施例34不同之处在于：将50mg,0.4mmol的吡嗪-2-羧酸替换为57mg，0.3mmol的4-二甲基氨基肉桂酸，根据方法c获得66mg黄色油状物，收率55％。
1H NMR(400MHz,CDCl3)δ7.56(d,J＝15.5Hz,1H),7.23(s,2H),7.14(d,J＝8.2Hz,3H),6.57(d,J＝7.0Hz,2H),6.06(d,J＝15.5Hz,1H),5.79(s,1H),4.49(d,J＝6.6Hz,1H),3.37(s,3H),2.96(s,6H),2.81(d,J＝7.8Hz,1H),2.60(s,2H),2.55–2.20(m,8H),2.11–1.99(m,2H),1.91(s,3H),1.81–1.69(m,3H),1.53–1.46(m,1H),1.41–1.35(m,1H),0.60(s,3H).
HRMS(ESI-TOF):calcd for C39H45N2O3[M+H]+589.3425；found 589.3414.
实施例48
2-Hydroxy-N-(4-((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-(prop-1-yn-1-yl)-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-11-yl)phenyl)-N-methyl-2-phenylacetamide(FZU-0010-052)
与实施例34不同之处在于：将50mg,0.4mmol的吡嗪-2-羧酸替换为61mg，0.4mmol的扁桃酸，根据方法c得到45mg白色固体，收率41％，mp:122.1–123.5℃。
1H NMR(400MHz,CDCl3)δ7.65–7.34(m,2H),7.23–7.05(m,3H),6.98–6.86(m,1H),6.85–6.69(m,2H),5.80(d,J＝10.2Hz,1H),5.02(s,1H),4.58–4.30(m,1H),3.33–3.20(m,2H),2.86–2.70(m,1H),2.67–2.56(m,1H),2.53–2.36(m,4H),2.34–2.21(m,3H),2.12–1.96(m,3H),1.90(s,3H),1.79–1.69(m,2H),1.54–1.33(m,2H),1.31–1.21(m,1H),0.94–0.83(m,1H),0.60(s,3H).
HRMS(ESI-TOF):calcd for C36H40NO4[M+H]+550.2952；found 550.2945.
实施例49
N-(4-((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-(prop-1-yn-1-yl)-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-11-yl)phenyl)-N-methyl-2-naphthamide(FZU-0025-003)
与实施例34不同之处在于：将50mg,0.4mmol的吡嗪-2-羧酸替换为42mg，0.24mmol的2-萘甲酸，根据方法c得到87mg白色固体，收率77％，,mp:129.3–130.5℃。1H NMR(400MHz,CDCl3)δ7.85(s,1H),7.72(d,J＝7.9Hz,1H),7.67(d,J＝7.8Hz,1H),7.53(d,J＝8.5Hz,1H),7.49–7.37(m,2H),7.27(d,J＝9.1Hz,1H),6.98(q,J＝8.5Hz,4H),5.73(s,1H),4.31(d,J＝7.2Hz,1H),3.55(s,3H),2.65(dt,J＝14.8,5.1Hz,1H),2.57–2.46(m,2H),2.45–2.20(m,5H),2.20–2.08(m,3H),2.02–1.92(m,2H),1.88(s,3H),1.76–1.62(m,2H),1.47–1.37(m,1H),1.30–1.24(m,1H),0.35(s,3H).
13C NMR(101MHz,CDCl3)δ199.37,170.41,156.53,145.25,143.49,142.59,133.57,133.08,132.30,129.63,128.60,127.87,127.63,127.27,127.09,127.02,126.34,125.63,123.11,82.61,82.24,80.03,49.58,46.87,40.08,39.28,39.17,38.86,38.39,36.75,31.12,27.37,25.76,23.33,13.66,3.90.HRMS(ESI-TOF):calcd for C39H40NO3[M+H]+570.3003；found 570.2968.
实施例50
N-(4-((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-(prop-1-yn-1-yl)-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-11-yl)phenyl)-N-methyl-[1,1'-biphenyl]-3-carboxamide(FZU-0025-004)
与实施例34不同之处在于：将50mg,0.4mmol的吡嗪-2-羧酸替换为48mg，0.24mmol的3-苯基苯甲酸，根据方法c得到90mg白色固体，收率76％，mp:126.9–127.9℃。
1H NMR(400MHz,CDCl3)δ7.49–7.25(m,7H),7.24–7.13(m,2H),7.05(d,J＝8.2Hz,2H),7.02–6.93(m,2H),5.75(s,1H),4.33(d,J＝7.1Hz,1H),3.52(s,3H),2.65(dt,J＝15.0,5.2Hz,1H),2.58–2.47(m,2H),2.43–2.30(m,3H),2.28–2.08(m,4H),2.03–1.95(m,2H),1.89(s,3H),1.77–1.63(m,2H),1.50–1.40(m,1H),1.30–1.26(m,1H),0.27(s,3H).
13C NMR(101MHz,CDCl3)δ199.40,170.51,156.54,145.21,143.43,142.62,140.34,140.11,136.34,129.70,128.83,128.24,128.21,127.85,127.79,127.62,127.49,127.09,126.93,123.18,82.63,82.16,80.09,49.65,46.85,40.07,39.16,38.94,38.33,36.76,31.14,27.38,25.80,23.34,22.71,13.65,3.91.
HRMS(ESI-TOF):calcd for C41H42NO3[M+H]+596.3159；found 596.3146.
实施例51
N-(4-((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-(prop-1-yn-1-yl)-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-11-yl)phenyl)-N,3,4-trimethylbenzamide(FZU-0025-005)
与实施例34不同之处在于：将50mg,0.4mmol的吡嗪-2-羧酸替换为36mg，0.24mmol的3,4-二甲基苯甲酸，根据方法c得到84mg白色固体，收率77％，mp:131.6–132.5℃。
1H NMR(400MHz,CDCl3)δ7.11(s,1H),7.04(d,J＝8.2Hz,2H),6.94(d,J＝8.4Hz,2H),6.91(s,1H),6.83(d,J＝7.8Hz,1H),5.77(s,1H),4.36(d,J＝7.2Hz,1H),3.45(s,3H),2.72(dt,J＝10.8,5.2Hz,1H),2.62–2.54(m,2H),2.50–2.34(m,3H),2.27–2.17(m,3H),2.15(s,3H),2.10(s,3H),2.06–1.95(m,3H),1.90(s,3H),1.80–1.65(m,2H),1.57–1.43(m,1H),1.38–1.30(m,1H),0.45(s,3H).
13C NMR(101MHz,CDCl3)δ199.33,170.55,156.51,145.37,143.10,142.90,138.54,135.83,133.01,130.23,129.58,128.63,127.69,126.86,126.56,123.06,82.59,82.23,79.98,49.58,46.85,40.06,39.26,39.17,38.83,38.35,36.74,31.10,27.35,25.75,23.34,22.63,19.65,13.62,3.84.
HRMS(ESI-TOF):calcd for C37H42NO3[M+H]+548.3159；found 548.3152.
实施例52
N-(4-((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-(prop-1-yn-1-yl)-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-11-yl)phenyl)-N-methyl-[1,1'-biphenyl]-4-carboxamide(FZU-0025-001)
将48mg,0.24mmol的4'-羟基联苯基-4-羧酸，83mg,0.2mmol的美她司酮和115mg,0.6mmol的EDCI加入到2.0mL的CH2Cl2中，PE/EtOAc＝1:1，按方法C制备得到87mg的产物，得率为73％，产物为白色固体，mp:125.5–126.5℃。
1H NMR(400MHz,CDCl3)δ7.48(d,J＝7.6Hz,2H),7.41(t,J＝7.5Hz,2H),7.37–7.29(m,5H),7.06(d,J＝8.2Hz,2H),7.01–6.93(m,2H),5.77(s,1H),4.37(d,J＝7.0Hz,1H),3.50(s,3H),2.74(dt,J＝14.8,5.0Hz,1H),2.62–2.52(m,2H),2.51–2.32(m,4H),2.28–2.18(m,3H),2.15–2.08(m,1H),2.04–1.95(m,2H),1.90(s,3H),1.80–1.65(m,2H),1.51–1.39(m,1H),1.36–1.26(m,1H),0.42(s,3H).
13C NMR(101MHz,CDCl3)δ199.37,170.30,156.58,145.25,143.46,142.62,142.32,140.08,134.55,129.71,129.45,128.92,127.85,127.07,126.27,123.17,82.65,82.24,80.02,49.70,46.98,40.08,39.39,39.17,38.95,38.28,36.80,31.15,27.40,25.86,23.39,14.00,3.91.
HRMS(ESI-TOF):calcd for C41H42NO3[M+H]+596.3159；found 539.3146.
实施例53
4-(tert-Butyl)-N-(4-((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-(prop-1-yn-1-yl)-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-11-yl)phenyl)-N-methylbenzamide(FZU-0025-002)
与实施例52不同之处在于：将48mg,0.24mmol的4'-羟基联苯基-4-羧酸替换为43mg,0.24mmol的对叔丁基苯甲酸，得到74mg的产物，得率为64％，产物为白色固体，mp:216.9-217.8℃。
1H NMR(400MHz,CDCl3)δ7.16(d,J＝8.2Hz,2H),7.11(d,J＝8.2Hz,2H),7.03(d,J＝8.1Hz,2H),6.94(d,J＝8.1Hz,2H),5.75(s,1H),4.36(d,J＝7.0Hz,1H),3.48(s,3H),2.73(dt,J＝14.7,5.1Hz,1H),2.63–2.51(m,2H),2.51–2.32(m,4H),2.26–2.16(m,3H),2.06–1.89(m,3H),1.88(s,3H),1.79–1.63(m,2H),1.53–1.39(m,1H),1.35–1.27(m,1H),1.20(s,9H),0.40(s,3H).
13C NMR(101MHz,CDCl3)δ199.30,170.69,156.52,152.84,145.32,143.17,142.83,132.87,129.67,128.75,127.73,127.10,124.53,123.17,82.64,82.30,80.01,49.70,46.96,40.06,39.33,39.17,38.95,38.16,36.85,34.71,31.17,27.39,25.84,23.43,13.96,3.93.
HRMS(ESI-TOF):calcd for C39H46NO3[M+H]+576.3472；found 576.3462.
实施例54
N-(4-((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-(prop-1-yn-1-yl)-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-11-yl)phenyl)-4-isopropyl-N-methylbenzamide(FZU-0025-006)
与实施例52不同之处在于：将48mg,0.24mmol的4'-羟基联苯基-4-羧酸替换为39mg,0.24
mmol的4-异丙基苯甲酸，得到82mg的产物，得率为73％，产物为白色固体，mp:237.9-238.9℃。
1H NMR(400MHz,CDCl3)δ7.16(d,J＝7.4Hz,2H),7.03(d,J＝7.5Hz,2H),6.99–6.86(m,4H),5.76(s,1H),4.36(d,J＝6.0Hz,1H),3.47(s,3H),2.87–2.69(m,2H),2.63–2.48(m,2H),2.48–2.29(m,4H),2.27–2.16(m,3H),2.14–2.06(m,1H),2.06–1.94(m,2H),1.88(s,3H),1.78–1.62(m,2H),1.51–1.38(m,1H),1.35–1.26(m,1H),1.13(d,J＝6.5Hz,6H),0.37(s,3H).
13C NMR(101MHz,CDCl3)δ199.33,170.70,156.54,150.63,145.36,143.21,142.83,133.23,129.66,129.03,127.74,127.08,125.66,123.15,82.63,82.30,80.01,49.67,46.95,40.07,39.33,39.17,38.92,38.18,36.82,33.92,31.14,27.39,25.82,23.80,23.76,23.42,13.87,3.91.
HRMS(ESI-TOF):calcd for C38H44NO3[M+H]+562.3316；found 562.3306.
实施例55
N-(4-((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-(prop-1-yn-1-yl)-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-11-yl)phenyl)-N-methyl-2-phenylacetamide(FZU-0025-012)
与实施例52不同之处在于：将48mg,0.24mmol的4'-羟基联苯基-4-羧酸替换为33mg,0.24mmol的苯乙酸，得到83mg的产物，得率为78％，产物为白色固体，mp:126.7-127.5℃。
1H NMR(400MHz,CDCl3)δ7.26–7.12(m,5H),7.11–6.85(m,4H),5.80(s,1H),4.46(d,J＝7.0Hz,1H),3.46(s,2H),3.24(d,J＝8.5Hz,3H),2.88–2.74(m,1H),2.68–2.57(m,2H),2.54–2.38(m,4H),2.36–2.17(m,4H),2.13–1.98(m,2H),1.92(s,3H),1.84–1.71(m,2H),1.59–1.45(m,1H),1.41–1.31(m,1H),0.57(s,3H).
13C NMR(101MHz,CDCl3)δ199.37,171.15,156.55,145.21,144.79,141.59,135.38,129.82,129.00,128.34,128.28,127.72,126.63,123.25,82.70,82.28,80.03,49.72,47.00,41.11,40.22,39.27,39.22,38.96,37.68,36.84,31.14,27.40,25.97,23.43,14.01,3.94.
HRMS(ESI-TOF):calcd for C36H40NO3[M+H]+534.3003；found 534.2997.
实施例56
N-(4-((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-(prop-1-yn-1-yl)-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-11-yl)phenyl)-N,3-dimethylbenzamide(FZU-0025-014)
与实施例52不同之处在于：将48mg,0.24mmol的4'-羟基联苯基-4-羧酸替换为33mg,0.24mmol的3-甲基苯甲酸，得到74mg的产物，得率为69％，产物为白色固体，mp:128.6-129.5℃。
1H NMR(400MHz,CDCl3)δ7.15(s,1H),7.07–6.97(m,3H),6.98–6.84(m,4H),5.76(s,1H),4.35(d,J＝7.1Hz,1H),3.46(s,3H),2.71(dt,J＝14.8,5.2Hz,1H),2.63–2.52(m,2H),2.51–2.28(m,4H),2.26–2.20(m,2H),2.19(s,3H),2.15–2.08(m,1H),2.07–1.93(m,3H),1.90(s,3H),1.79–1.66(m,2H),1.53–1.42(m,1H),1.37–1.28(m,1H),0.42(s,3H).
13C NMR(101MHz,CDCl3)δ199.44,170.72,156.59,145.38,143.25,142.71,137.41,135.65,130.44,129.66,129.56,127.74,127.36,126.98,125.99,123.14,82.67,82.27,80.06,49.67,46.92,40.09,39.27,39.19,38.90,38.30,36.80,31.15,27.40,25.81,23.40,21.33,13.72,3.92.
HRMS(ESI-TOF):calcd for C36H40NO3[M+H]+534.3003；found 534.2996.
实施例57
N-(4-((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-(prop-1-yn-1-yl)-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-11-yl)phenyl)-N,4-dimethylbenzamide(FZU-0025-015)
与实施例52不同之处在于：将48mg,0.24mmol的4'-羟基联苯基-4-羧酸替换为33mg,0.24mmol的对甲苯甲酸，得到73mg的产物，得率为68％，产物为白色固体，mp:125.7-126.8℃。
1H NMR(400MHz,CDCl3)δ7.20–7.09(m,2H),7.08–6.98(m,2H),6.98–6.80(m,4H),5.77(s,1H),4.37(d,J＝7.1Hz,1H),3.48(s,3H),2.81–2.68(m,1H),2.65–2.50(m,2H),2.50–2.32(m,4H),2.31–2.17(m,6H),2.16–2.10(m,1H),2.06–1.95(m,2H),1.89(s,3H),1.81–1.67(m,2H),1.52–1.40(m,1H),1.39–1.28(m,1H),0.43(s,3H).
13C NMR(101MHz,CDCl3)δ199.44,170.59,156.58,145.43,143.40,142.85,139.90,132.78,129.68,129.05,128.27,127.82,127.04,123.15,82.69,82.29,80.06,49.65,46.95,40.13,39.40,39.23,38.91,38.32,36.81,31.16,27.41,25.83,23.42,21.42,13.72,3.92.
HRMS(ESI-TOF):calcd for C36H40NO3[M+H]+534.3003；found 534.3000.
实施例58米非司酮衍生物对三阴性乳腺癌细胞的作用
以人三阴性乳腺癌细胞系HCC1937和SUM149PT为测试细胞系(细胞购自美国模式培养物集存库，ATCC)。
细胞培养方法：取出液氮中冻存的HCC1937细胞，在37℃的温水中解冻，将细胞冻存管置于离心机中，500g离心5min，弃去上清液，加入1mL RPMI-1640完全培养液，轻轻吹打均匀，将细胞悬液加入培养皿中，补加9mL RPMI-1640完全培养液，将培养皿置于5％CO2、37℃培养箱中培养。取出液氮中冻存的SUM149PT细胞，在37℃的温水中解冻，将细胞冻存管置于离心机中，500g离心5min，弃去上清液，加入1mL F-12完全培养液，轻轻吹打均匀，将细胞悬液加入培养皿中，补加9mL F-12完全培养液，将培养皿置于5％CO2、37℃培养箱中培养。细胞毒性实验：将HCC1937或SUM149PT细胞以3×104个细胞/孔的密度接种到48孔培养板中，培养24h后，更换培养液为新鲜血清培养液，加入0、5μM、10μM、15μM、20μM五个浓度的米非司酮或用本发明方法制备所得的米非司酮系列衍生物，其中FZU-0000系列3种，FZU-0002系列10种，FZU-0010系列39种，FZU-0025系列13种，孵育48h后，吸弃孔中溶液，每孔加入200μl 10％三氯醋酸(TCA)，室温放置1小时或4℃过夜固定；固定好的细胞吸弃固定液，以蒸馏水清洗5遍，室温晾干；每孔加入200μl 0.4％(w/v)的SRB染液(1％的乙酸配制)，室温染色30min后倒掉染液，用1％(v/v)乙酸冲洗5次，去除未结合的染料，室温晾干后每孔加入200μl非缓冲Tris-base碱液(10mM，pH10.5)溶解与细胞蛋白结合的染料，水平摇床上振荡20min，采用酶标仪530nm处测定光吸收值(A)，按照以下公式计算：细胞存活率％＝(试验组平均A值/空白对照组平均A值)×100％。结果如表1所示，结果显示，HCC1937和SUM149PT细胞的存活率与米非司酮衍生物化合物浓度呈显著相关性，化合物浓度越高，存活率越低，也表明部分米非司酮衍生物较米非司酮抗肿瘤活性强，浓度低
表1：米非司酮衍生物对三阴性乳腺癌细胞扩增的影响
a Triple-negative breast cancer(TNBC)cell lines:HCC1937andSUM149PT.Software:MasterPlex ReaderFit 2010,MiraiBio,Inc.The values are themean±SE of at least three independent experiments.b If a specific compoundis given value>20,it indicates that a specific IC50cannot be calculated fromthe data points collected,meaning“no effect”.NT代表未经测试(No Test)。

Claims (10)

1.米非司酮衍生物，其结构式特征如下：
其中，R为酰基或者磺酰基；
当R为酰基时，其具体结构特征为R1CO-，R1为C1-C6烷基、氯代C1-C6烷基、苄基、萘基、苯基、卤代苯基、C1-C6烷基取代苯基、甲氧基取代苯基、羧酸取代苯基、硝基取代苯基、N，N-二甲基取代苯基、苯基取代苯基、烯烃、苯基取代烯烃或杂环，包括噻唑、2-噻吩、吡嗪、吡啶、卤代吡啶；
当R为磺酰基时，其具体结构特征为R2SO2-，R2为苯基、C1-C6烷基取代苯基。
2.根据权利要求1所述的米非司酮衍生物，当R为酰基时，其中R1为氯代C1-C6烷基、卤代苯基、萘基、硝基取代苯基、C1-C6烷基取代苯基或苯基取代苯基。
3.根据权利要求2所述的米非司酮衍生物，R1为氯代甲烷基。
4.根据权利要求2所述的米非司酮衍生物，R1为氯或溴代苯基。
5.根据权利要求4所述的米非司酮衍生物，R1为3，4氯代苯基或2-溴4-氯代苯基。
6.根据权利要求2所述的米非司酮衍生物，R1为苯基。
7.根据权利要求2所述的米非司酮衍生物，R1为甲基取代苯基。
8.根据权利要求7所述的米非司酮衍生物，R1为甲基取代3-苯基或甲基取代4-苯基。
9.根据权利要求1所述的米非司酮衍生物在制备治疗与KLF5调控的肿瘤药物中的用途。
10.根据权利要求1所述的米非司酮衍生物在制备治疗三阴性乳腺癌药物中的用途。
CN201610821694.4A 2016-09-13 2016-09-13 米非司酮衍生物及其用途 Active CN106397527B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610821694.4A CN106397527B (zh) 2016-09-13 2016-09-13 米非司酮衍生物及其用途

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610821694.4A CN106397527B (zh) 2016-09-13 2016-09-13 米非司酮衍生物及其用途

Publications (2)

Publication Number Publication Date
CN106397527A true CN106397527A (zh) 2017-02-15
CN106397527B CN106397527B (zh) 2019-07-26

Family

ID=58000001

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610821694.4A Active CN106397527B (zh) 2016-09-13 2016-09-13 米非司酮衍生物及其用途

Country Status (1)

Country Link
CN (1) CN106397527B (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102544591B1 (ko) * 2023-02-08 2023-07-17 주식회사 에스씨엘테라퓨틱스 신규 화합물 및 이의 용도

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
MAXWELL N. SKOR等: "Glucocorticoid Receptor Antagonism as a Novel Therapy for Triple-Negative Breast Cancer", 《CLINICAL CANCER RESEARCH》 *
RITA NANDA等: "A randomized phase I trial of nanoparticle albumin‑bound paclitaxel with or without mifepristone for advanced breast cancer", 《SPRINGERPLUS》 *
RONG LIU等: "Mifepristone Suppresses Basal Triple-Negative Breast Cancer Stem Cells by Down-regulating KLF5 Expression", 《THERANOSTICS》 *
THOMAS W. VON GELDERN等: "Liver-Selective Glucocorticoid Antagonists: A Novel Treatment for Type 2 Diabetes", 《J. MED. CHEM.》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102544591B1 (ko) * 2023-02-08 2023-07-17 주식회사 에스씨엘테라퓨틱스 신규 화합물 및 이의 용도

Also Published As

Publication number Publication date
CN106397527B (zh) 2019-07-26

Similar Documents

Publication Publication Date Title
CN105399694B (zh) 药物Lesinurad轴手性对映体
CN109563060B (zh) Ido1抑制剂及其制备方法和应用
US8816122B2 (en) Prostratin analogs, bryostatin analogs, prodrugs, synthetic methods, and methods of use
CN103038210B (zh) 作为消炎、免疫调节和抗增殖剂的新型化合物的钙盐
BR112012025496B1 (pt) composto inibidor quinase e composição farmacêutica que o compreende
CN106167504A (zh) 非环核苷磷酰胺d‑氨基酸酯衍生物及其盐的制备以及在抗病毒方面的应用
CN111116449A (zh) 一种新型色胺衍生物及其制备方法和应用
Tang et al. Design, synthesis and biological evaluation of novel xanthine oxidase inhibitors bearing a 2-arylbenzo [b] furan scaffold
CN110256313A (zh) 一种光敏剂前药化合物及其制备方法和应用
CN102614198B (zh) (4-取代苯甲酰)氟苯水杨酰胺类化合物在制备抗肺癌药物中的应用
CN106536498A (zh) 作为hsp90抑制剂和hsp70诱导剂的具有经修饰醚基的联苯酰胺
CN103193691A (zh) 磺胺类化合物、药物组合物及其制法和应用
ES2782357T3 (es) Inhibidores de IRE 1 alfa
CN108069954B (zh) 含no供体的喹唑啉酮化合物
CN107721975A (zh) 具有抗肿瘤活性的brd4小分子抑制剂、合成方法及其应用
CN104230952A (zh) 含有嘧啶骨架的化合物及其制备方法和用途
Yan et al. Design, synthesis, and biological evaluation of novel diphenylamine derivatives as tubulin polymerization inhibitors targeting the colchicine binding site
CN109942565B (zh) 一种吲哚胺-2,3-双加氧酶抑制剂及其制备方法和用途
CN104829671B (zh) No供体型的吉西他滨/fta/呋咱缀合物及制备方法和用途
CN106397527A (zh) 米非司酮衍生物及其用途
CN106967143B (zh) 结构新颖的pyxinol衍生物及其制备方法和用途
CN104902889A (zh) 用于治疗癌症的β-水解酶抑制剂
CN103110621A (zh) 茶双氯香酰胺和茶双溴香酰胺等在制备具有预防和治疗癌症等疾病的产品中的应用
CN102614199B (zh) (4-取代苯甲酰)氟苯水杨酰胺类化合物在制备抗宫颈癌药物中的应用
CN113583007B (zh) 一种吡咯并嘧啶类btk抑制剂及其制备方法与应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant